Review Article

Systematic Review: Guideline-Based Approach for the Management of Asthma and Subtypes via Chinese Medicine

Lin Ho Wong,1,2 Louisa Tay,2 Robby Miguel W. J. Goh,3 Tai Joum Tan,3 Ruishu Zhou,2 Aaron Kwun Hang Ho,4 and Pang Ong Wong1,5

1Ong Fujian Chinese Physician Hall, Singapore
2Singapore College of Traditional Chinese Medicine, Singapore
3University College London, London, UK
4Ministry of Health Holdings, Singapore
5Chang Chun University of Traditional Chinese Medicine, Changchun, China

Correspondence should be addressed to Lin Ho Wong; nate.wong90@live.com.sg

Received 9 June 2020; Accepted 30 December 2020; Published 8 January 2021

Academic Editor: Vincenzo De Feo

Copyright © 2021 Lin Ho Wong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Asthma is a chronic condition that results in the inflammation and narrowing of airways, often clinically presenting as wheeze and shortness of breath. Little is known of the mechanisms of action (MOA) of herbs used to treat asthma. The aim of this study is to review existing data regarding known MOA of traditional Chinese medicine which will aid in the understanding of possible interactions between Western drugs and Chinese herbs as well as the standardization of management via a proposed guideline to improve patient safety and possible synergism in the long term. Methods. We searched through 5 databases for commonly prescribed herbs and formulas for asthma and narrowed down the search to identify the underlying MOA of individual herbs that could specifically target asthma symptoms. We included studies that stated the MOA of individual herbs when used for treating symptoms of asthma, excluding them if they are described as part of a formula. Results. A total of 26 herbs commonly prescribed for asthma with known mechanism of action were identified. Herbs used for asthma were found to have similar MOA as that for drugs. Based on existing GINA guidelines, a guideline is proposed which includes a total of 5 steps depending on the severity of asthma and the herbs’ MOA. 16 formulas were subsequently identified for the management of asthma, which consist of 12 "stand-alone" and 4 "add-on" formulas. "Stand-alone" formulas used independently for asthma generally follow the GINA guidelines but do not proceed beyond step 3. These formulas consist mainly of beta-agonist and steroid-like effects. "Add-on" formulas added as adjunct to "stand-alone" formulas, however, mainly act on T helper cells or have steroid-like effects. Conclusion. Through the understanding of MOA of herbs and their respective formulas, it will ensue greater patient safety and outcomes.

1. Introduction

There has been an increasing trend in the use of complementary and alternative medicine (CAM) [1] since its acknowledgement by the World Health Organization (WHO) in 2018 [2]. Herbs are being used by 75% of the people in the world for their basic healthcare needs [3]. Despite the dominance of Western evidence-based medicine in healthcare settings, people occasionally seek traditional Chinese medicine (TCM) treatments, a widely used form of CAM, for medical conditions such as chronic pain and allergies, including, but not limited to, asthma. Asthma is a heterogeneous disease that is characterized by chronic, reversible airway inflammation that involves eosinophil granulocytes, mast cells, T cells, and an array of cytokines. As curative treatments for asthma are still not available, patients are increasingly seeking CAM for add-on treatments, resulting in growing concerns over the concomitant use of Western medicine and CAM herbs [4]. Furthermore, most CAM herbs used for asthma have unknown mechanism of actions (MOA). This could potentially lead to dangerously high concentration of constituents with the same MOA, which may lead to severe side effects.
While Western doctors typically manage asthma using the Global Initiative for Asthma (GINA) guidelines based on the disease severity, TCM adopts a less guideline-based and more individualized therapy via a holistic view of the patient’s pathophysiology, resulting in a discrepancy in herbal prescribing between TCM physicians [5]. With increasing scientific evidence to support the use of TCM for asthma [6], it is crucial for both medical doctors and TCM physicians to be aware of the potential risks that come with the simultaneous use of prescribed drugs and herbal medicine.

This review aims to categorise commonly used herbs and empirical prescriptions of TCM based on known MOA of Western medicines to allow both Western and TCM physicians to have a better understanding of how drugs and herbs interact. This will hopefully lead to increased patient safety and possible synergism in the long run, giving patients more choices for an individually tailored treatment and better treatment outcomes.

2. Methods

2.1. Criteria for considering Studies for This Review

2.1.1. Types of Studies. All studies eliciting the mechanism of action of a specific herb in the context of asthma, regardless of the model. Studies which involved the use of multiple herbs simultaneously (i.e., formulas) were excluded.

2.2. Search Methods for Identification of Studies

2.2.1. Electronic Searches. For this review, we searched EMBASE, PubMed, CENTRAL, Wanfang, and China National Knowledge Infrastructure (CNKI).

2.3. Identifying the Herbs. We first conducted a search to identify herbs which are currently commonly prescribed by TCM physicians by identifying systematic reviews on frequently used herbs or formulas and extracted the relevant herbs from the formulas, using the terms “asthma AND TCM OR Traditional Chinese Medicine OR alternative medicine” in EMBASE, PubMed, CENTRAL, Wanfang, and CNKI (Figure 1). The list was subsequently confirmed with a senior TCM physician specialising in TCM Formula-logy.

We then extracted the Latin and Mandarin names of the herbs used and identified those used primarily for the treatment of asthma, before searching electronic databases for their mechanisms of action (Figure 2). Herbs prescribed for supportive treatment were excluded.

2.4. EMBASE, PubMed, and Cochrane

2.4.1. CNKI (Overseas CNKI) and Wanfang (Based on the Translations of the Keywords Used in English Medium)

(1) “Glycyrrhiza uralensis” AND “asthma”
(2) “Prunus armeniaca” AND “asthma”
(3) “Pinellia ternata” AND “asthma”
(4) “Asarum sieboldii” AND “asthma”
(5) “Pheretima aspergillum” AND “asthma”
(6) “Aster tataricus” AND “asthma”
(7) “Fritillaria cirrhosa” AND “asthma”
(8) “Lepidium apetalum” AND “asthma”
(9) “Pericarpium Citri Reticulatae” AND “asthma”
(10) “Cortex Mori” AND “asthma”
(11) “Ephedra sinica” AND “asthma”
(12) “Zingiber officinale” AND “asthma”
(13) “Tussilago farfara” AND “asthma”
(14) “Platycodon grandifloras” AND “asthma”
(15) “Fritillaria thunbergii” AND “asthma”
(16) “Paeonia lactiflora” AND “asthma”
(17) “Magnolia officinalis” AND “asthma”
(18) “Bupleurum chinense” AND “asthma”
(19) “Scutellaria baicalensis” AND “asthma”
(20) “Perilla frutescens” AND “asthma”
(21) “Anemarrhena Rhizoma” AND “asthma”
(22) “Gypsum fibrosum” AND “asthma”
(23) “Eriobotryae Folium” AND “asthma”
(24) “Cinnamomi Ramulus” AND “asthma”
(25) “Zingiberis rhizoma” AND “asthma”
(26) “Schisandra Fructus” AND “asthma”

We did not impose any language or publication restrictions.

2.5. Data Collection and Analysis

2.5.1. Selection of Studies. Four review authors (TJ, L, RS, and RM) independently reviewed the titles, abstracts, and keywords of all records retrieved to determine the studies to be assessed. We retrieved full articles for further assessment if the information given suggested that the study:

(1) Discussed asthma
(2) And administered any of 26 Chinese herbs identified through the initial search

A fifth review author (LH) acted as arbiter and resolved any differences in opinion.

2.5.2. Data Analysis. We first identified the herbs relevant to treating asthma by the formulas which contain them, for reference purposes (Table 1). We then categorised the herbs according to their mechanisms of action (Table 2), plotted a schematic representation of the herbs on the asthma immunopathological pathway (Figure 3), and then compared them against GINA guidelines to identify clinical situations where herbs could see the potential use (Figure 4).
3. Results

3.1. Results of the Search to Identify Herbs of Interest. Our initial searches in online databases identified 6843 studies, of which 128 systematic reviews were relevant to our topic, yielding 55 herbs (Figure 1).

3.2. Included Herbs. Of the 55 herbs, 26 were used primarily for asthma treatment. These included *Glycyrrhiza uralensis* [7–24], *Prunus armeniaca* [25, 26], *Pinellia ternata* [27], *Asarum sieboldii* [28, 29], *Pheretima aspergillum* [30–37], *Aster tataricus* [38, 39], *Fritillaria cirrhosa* [40–43], *Lepidium apetalum* [44], *Pericarpium Citri Reticulatae* [45–47], *Cortex Mori* [48–52], *Ephedra sinica* Stapf [53–56], *Zingiber officinale Roscoe* [57], *Tussilago farfara* [58–61], *Platycodon grandifloras* [62–65], *Fritillaria thunbergii* [66, 67], *Paeonia lactiflora* [68–71], *Magnolia officinalis* [72–77], *Bupleurum chinense* [78, 79], *Scutellaria baicalensis* [80–86], *Anemarrhena Rhizoma* [87, 88], *Gypsum fibrosum*, *Eriobotryae Folium* [89], *Cinnamomi Ramulus* [90], *Zingiberis rhizoma*, *Schisandra Fructus* [91–93], and *Perilla frutescens* [94].

3.3. Results of the Search for Herb Mechanisms of Action

3.3.1. Included Studies. Searching online databases yielded 8961 studies, of which 149 met the inclusion criteria (Figure 2). No studies were found for the herbs *Gypsum fibrosum* and *Zingiberis rhizoma*.

3.3.2. Mechanisms of Action. We first extracted the proposed mechanisms of action of the herbs (Table 1) and categorised them according to the known main mechanisms of action of Western medicines important in the treatment
Figure 2: Study flow diagram for the identification of articles of commonly used herbs.

Table 1: Summary of MOA of herbs frequently used in asthma.

<table>
<thead>
<tr>
<th>Herb species</th>
<th>Mechanism of action</th>
</tr>
</thead>
</table>
| Glycyrrhiza uralensis | *In murine models*  
1. Bronchodilation  
LPS-induced NO production  
Attenuates acetylcholine- and carbachol-induced contractions  
2. Anti-inflammatory  
Inhibit T lymphocytes, eosinophils, IgE, IL-13, and TNF-α  
Upregulate caspase-3 and Bax  
Steroid-like activities  
Downregulate Bcl-2  
3. Mucolytic  
Inhibit MUC5AC gene expression, production and secretion via regulation of NF-κB, STAT6, and HDAC2 |
| | *In guinea pig models*  
1. Bronchodilation |
| | *Human airway epithelial cells*  
1. Mucolytic  
Inhibit PMA-induced MUC5AC mucin production |
| | *Human peripheral blood mononuclear cells*  
1. Anti-inflammatory  
Phytohaemagglutinin-induced proliferation and inhibition of TNF-alpha, IFN-gamma, and IL-10 production |
| | *In vitro*  
1. Anti-inflammatory  
Inhibit memory Th2 responses  
Inhibit IL-4 and Eotaxin-1 secretion |
<table>
<thead>
<tr>
<th>Herb species</th>
<th>Mechanism of action</th>
</tr>
</thead>
</table>
| **Prunus armeniaca** | *In murine models*  
(1) Anti-inflammatory  
Reduce recruitment of eosinophils, macrophages, and lymphocytes  
Inhibit MAPK signalling and IL-4 activation  
Activate IFN-γ |
| **Pinellia ternata** | *In murine models*  
(1) Anti-inflammatory  
Reduce recruitment of eosinophils  
Reduce IL-4 activation and IFN-γ activation |
| **Asarum sieboldii** | *In guinea pig models*  
(1) Anti-inflammatory  
Inhibit IL-4 activation and histamine release  
(2) Signalling pathway regulation  
Regulate MMP-9 and TIMP-1 signalling |
| **Pheretima aspergillum** | *In murine models*  
(1) Anti-inflammatory  
Inhibit IL-4, IL-5, IgE, and TNF-α activation  
Inhibit eosinophil activation  
Regulate Th1/Th2 balance  
Inhibit NF-kB activation  
Inhibit production of NO, PGE2, TNF-α, iNOS, and COX-2  
Inhibit release of IL-1B and IL-6  
(2) Mucolytic  
Decrease collagen deposition  
Decrease mucin glycogen expression  
*In guinea pig models*  
(1) Anti-inflammatory  
Regulate IFN-γ, IL-4, and LTB4 production  
*In human models*  
(1) Anti-inflammatory  
Inhibit TGF-B1 and SMAD2 |
| **Aster tataricus**   | *In vitro*  
(1) Anti-inflammatory  
Suppress NO production  
Inhibit production of PGE2, IL-6, IL-1B  
Inhibit expression of iNOS and COX-2 by inhibition of NF-KB activation  
(2) Signalling blockade  
Prevent activation of MAPK signalling cascade via inhibition of phosphorylation of c-Jun N-terminal kinases, extracellular signal-regulated kinases, and p38  
(3) Bronchodilation  
Activate of B2-adrenoceptors |
| **Fritillaria cirrhosa** | *D. Don*  
*In murine models*  
(1) Anti-inflammatory  
Suppress TH2 cytokines (IL-4, IL-5, and IL-13)  
Suppress IgE, histamine production  
Reduce eosinophilic accumulation  
Increase IFN-γ production  
(2) Block signalling pathways  
Inhibit ERK/MAPK signalling activation  
(3) Downregulate NOTCH 2 expression  
(4) Inhibit MMP-2, MMP-9, and TIMP-1 |
| **Lepidium apetalum** | *In murine models*  
(1) Anti-inflammatory  
Reduce expression of type 2 cytokines  
Inhibit differentiation and activation of Th2 cytokines |
<table>
<thead>
<tr>
<th>Herb species</th>
<th>Mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>In murine models</strong></td>
</tr>
<tr>
<td></td>
<td>(1) Anti-inflammatory</td>
</tr>
<tr>
<td></td>
<td>Suppress eosinophil production</td>
</tr>
<tr>
<td>Pericarpium Citri Reticulatae</td>
<td><strong>In guinea pig models</strong></td>
</tr>
<tr>
<td></td>
<td>(1) Anti-inflammatory</td>
</tr>
<tr>
<td></td>
<td>Downregulate expression of eosinophils and serum IgE, IL-4, and IL-5 levels</td>
</tr>
<tr>
<td></td>
<td>(2) Bronchodilation</td>
</tr>
<tr>
<td></td>
<td>Activation of B2-adrenoceptors</td>
</tr>
<tr>
<td></td>
<td><strong>In murine models</strong></td>
</tr>
<tr>
<td></td>
<td>(1) Anti-inflammatory</td>
</tr>
<tr>
<td></td>
<td>Enhance the CD4(+)CD25(+)Foxp3(+) regulatory T cells and inhibition of Th2 cytokines such as interleukin (IL)-4, -5 and -13</td>
</tr>
<tr>
<td></td>
<td>(2) Anticholinergic</td>
</tr>
<tr>
<td>Cortex Mori</td>
<td><strong>In murine models</strong></td>
</tr>
<tr>
<td></td>
<td>(1) Anti-inflammatory</td>
</tr>
<tr>
<td>Ephedra sinica Stapf</td>
<td>Regulate levels of inflammatory factors such as OVA-IgE, IL-4, and IL-13 and downregulate the expression of p65 NF-k B protein</td>
</tr>
<tr>
<td></td>
<td>(2) Bronchodilator</td>
</tr>
<tr>
<td></td>
<td>Activate α-, β1-, and B2-adrenoceptors</td>
</tr>
<tr>
<td>Zingiber officinale Roscoe</td>
<td><strong>In murine models</strong></td>
</tr>
<tr>
<td></td>
<td>(1) Anti-inflammatory</td>
</tr>
<tr>
<td></td>
<td>Inhibit Th2-mediated immune response</td>
</tr>
<tr>
<td></td>
<td>(2) Bronchodilation</td>
</tr>
<tr>
<td></td>
<td>Reduce Ca2+ influx in smooth muscle and promote βagonist-induced relaxation in human airway smooth muscle by suppressing phosphodiesterase 4D</td>
</tr>
<tr>
<td>Tussilago farfara</td>
<td><strong>In murine models</strong></td>
</tr>
<tr>
<td></td>
<td>(1) Anti-inflammatory</td>
</tr>
<tr>
<td></td>
<td>Regulate IgE, IL-4, and IL-13 levels</td>
</tr>
<tr>
<td></td>
<td>Downregulate the expression of p65 NF-kB protein</td>
</tr>
<tr>
<td></td>
<td>Inhibit NO, MAPKs, and NF-kB</td>
</tr>
<tr>
<td></td>
<td>Suppress expression of PGE2, TNF-α, and HMGB1</td>
</tr>
<tr>
<td></td>
<td>Reduce production of IL-4, IL-5, IL-13, and IL-17</td>
</tr>
<tr>
<td></td>
<td>Reduce IgE in serum by regulating Th1/Th2 cells</td>
</tr>
<tr>
<td></td>
<td>Increase HO-1 levels affecting Nrf2/HO-1 pathway</td>
</tr>
<tr>
<td></td>
<td>(2) Mucolytic</td>
</tr>
<tr>
<td></td>
<td>Decrease mucin production by regulating NF-kB</td>
</tr>
<tr>
<td>Platycodon grandifloras</td>
<td><strong>In guinea pig models</strong></td>
</tr>
<tr>
<td></td>
<td>Promote and regulate release of LXA4</td>
</tr>
<tr>
<td></td>
<td>Reduce oxygen-free radicals</td>
</tr>
<tr>
<td></td>
<td>Promote secretion of IFN-γ</td>
</tr>
<tr>
<td></td>
<td>Regulate Th1/Th2 balance</td>
</tr>
<tr>
<td>Fritillaria thunbergii</td>
<td><strong>In guinea pig models</strong></td>
</tr>
<tr>
<td></td>
<td>Inhibit PDE and prevent inactivation of cAMP</td>
</tr>
<tr>
<td>Paeonia lactiflora</td>
<td><strong>In murine models</strong></td>
</tr>
<tr>
<td></td>
<td>(1) Anti-inflammatory</td>
</tr>
<tr>
<td></td>
<td>Inhibit IL-22 and IL-13</td>
</tr>
<tr>
<td>Magnolia officinalis</td>
<td><strong>In murine models</strong></td>
</tr>
<tr>
<td></td>
<td>(1) Anti-inflammatory</td>
</tr>
<tr>
<td></td>
<td>Inhibit IL-4, IL-6, and IL-17</td>
</tr>
<tr>
<td></td>
<td>Decrease serum MDA level</td>
</tr>
<tr>
<td></td>
<td>Increase SOD and GSH-Px/p-JNK, NF-xB, caspase-3, and yH2 Ax levels</td>
</tr>
<tr>
<td></td>
<td>Inhibition of the PI3 K/Akt signalling pathway by TLR2 and TLR4 receptors-Steroid-like activities</td>
</tr>
</tbody>
</table>
of asthma. Based on known mechanisms, the herbs were divided broadly into beta-adrenergic agonist, steroid-like, anticholinergics, PDE antagonist, leukotriene antagonist, and herbs with monoclonal effects or those affecting signalling pathways (Table 2). The schematic representation on how herbs act on the immunopathological pathways of asthma is depicted in Figure 3. The herbs act mainly on IL-4, IL-5, IL-13, and IL-17A and T cells on asthmatic pathways, which act to mobilize inflammatory cells, tissue repair, and remodelling, causing bronchial hyperreactivity and induction of chemokines.

3.4. Proposed Guidelines in Relation to GINA Guidelines. The proposed guidelines (Figure 4), based on existing GINA guidelines, describe a stepwise approach to treating asthma, where increments in medication are made if existing treatment is insufficient for controlling a patient’s symptoms [95].

Step 1 involves using a low to moderate dose of beta-2-adrenergic agonist as required. Herbs which work similarly include Aster tataricus, Pericarpium Citri Reticulatae, Ephedra sinica Stapf, Zingiber officinale Roscoe, Tussilago farfara, and Scutellaria baicalensis.

Step 2 involves the addition of a low dose of corticosteroids. This can be achieved by adding Magnolia officinalis to the existing herbs or possibly by substituting them with Glycyrrhiza uralensis alone.

Step 3 involves increasing the dose of the beta-2-adrenergic agonist to a moderate-high dose and either using a medium dose of corticosteroid or adding a leukotriene receptor antagonist (LTRA) to the low-dose corticosteroid. Pheretima aspergillum is an LTRA and could potentially be useful.

Step 4 involves the addition of either an anticholinergic or an LTRA or increasing to a moderate dose of corticosteroid, whichever was not undertaken during step
<table>
<thead>
<tr>
<th>Chinese name</th>
<th>Latin name</th>
<th>MOA targeting asthmatic subgroups</th>
<th>Targeted asthmatic phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>β-Adrenergic agonist</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zi Wan</td>
<td><em>Aster tataricus</em> L. f.</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Chen Pi</td>
<td><em>Pericarpium Citri Reticulatae</em></td>
<td>(1) Inhibits IL-5 and reduction of eosinophil</td>
<td>(1) Idiopathic eosinophilic asthma</td>
</tr>
<tr>
<td>Ma Huang</td>
<td><em>Ephedra sinica</em> Stapf</td>
<td>Inhibits IL-4 and IL-13</td>
<td>(2) Allergen exacerbated asthma</td>
</tr>
<tr>
<td>Sheng Jiang</td>
<td><em>Zingiber officinale Roscoe</em></td>
<td>N/A</td>
<td>Allergen exacerbated asthma</td>
</tr>
<tr>
<td>Kuan Dong Hua</td>
<td><em>Tussilago farfara</em></td>
<td>(1) Inhibits IL-4, IL-13, and IgE</td>
<td>(1) Allergen exacerbated asthma</td>
</tr>
<tr>
<td>Huang Qin</td>
<td><em>Scutellaria baicalensis</em></td>
<td>(2) Inhibits IL-5</td>
<td>(2) Idiopathic eosinophilic asthma</td>
</tr>
<tr>
<td><strong>Steroidal effects</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hou Po</td>
<td><em>Magnolia officinalis</em></td>
<td>(1) Inhibits IL-4 and IL-13</td>
<td>(3) Neutrophilic asthma</td>
</tr>
<tr>
<td><strong>PDE inhibitor</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhe Bei</td>
<td><em>Fritillaria thunbergii</em></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>β-Adrenergic and steroidal effects</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gan Cao</td>
<td><em>Glycyrrhiza uralensis</em></td>
<td>(1) Inhibits IgE and IL-13</td>
<td>(1) Allergen exacerbated asthma</td>
</tr>
<tr>
<td><strong>Anticholinergic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sang Bai Pi</td>
<td><em>Cortex Mori</em></td>
<td>(2) Inhibits IL-5</td>
<td>(2) Idiopathic eosinophilic asthma</td>
</tr>
<tr>
<td><strong>Leukotriene antagonist</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Di Long</td>
<td><em>Pheretima aspergillum</em></td>
<td>(1) Leukotriene antagonist</td>
<td>(3) Neutrophilic asthma</td>
</tr>
<tr>
<td><strong>Inhibition of IL-4</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xi Xin</td>
<td><em>Asarum sieboldii</em></td>
<td>Inhibits IL-4 and histamine release</td>
<td>Allergen exacerbated asthma</td>
</tr>
<tr>
<td>Ban Xia</td>
<td><em>Pinellia ternata</em></td>
<td>Inhibits IL-4</td>
<td>Allergen exacerbated asthma</td>
</tr>
<tr>
<td>Ku Xing Ren</td>
<td><em>Prunus armeniaca</em></td>
<td>Inhibits IL-4</td>
<td>Allergen exacerbated asthma</td>
</tr>
<tr>
<td><strong>Inhibition of IL-17</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wu Wei Zi</td>
<td><em>Schisandra Fructus</em></td>
<td>Inhibits IL-17</td>
<td>Neutrophilic asthma</td>
</tr>
<tr>
<td><strong>Regulation of T helper cells</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ting Li Zi</td>
<td><em>Lepidium apetalum</em></td>
<td>Reduces the expression of Th2 cytokines and inhibits differentiation and activation of Th2 cells.</td>
<td>Allergen exacerbated asthma</td>
</tr>
<tr>
<td>Su Zi</td>
<td><em>Perilla frutescens</em></td>
<td>Suppression of allergen-specific Th2 response</td>
<td>Allergen exacerbated asthma</td>
</tr>
<tr>
<td>Pi Pa Ye</td>
<td><em>Eriobotryae Folium</em></td>
<td>Reduction of CD4+, rises CD 8+ , and alters CD4+/ CD8+ dysfunction</td>
<td>Allergen exacerbated asthma</td>
</tr>
<tr>
<td><strong>Multiple monoclonal effects for asthma</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhi Mu</td>
<td><em>Anemarrhena Rhizoma</em></td>
<td>(1) Inhibits IL-5 and reduction of eosinophil</td>
<td>(1) Idiopathic eosinophilic asthma</td>
</tr>
<tr>
<td>Jie Geng</td>
<td><em>Platycodon grandifloras</em></td>
<td>(2) Inhibits histamine release, IgE, IL-4, and IL-13</td>
<td>(2) Allergen exacerbated asthma</td>
</tr>
<tr>
<td>Shao Yao</td>
<td><em>Paeonia lactiflora</em></td>
<td>(1) Inhibits IL-4 and IL-13</td>
<td>(1) Allergen exacerbated asthma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(2) Inhibits IL-5</td>
<td>(2) Idiopathic eosinophilic asthma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(3) Inhibits IL-17</td>
<td>(3) Neutrophilic asthma</td>
</tr>
</tbody>
</table>
3. Cortex Mori has anticholinergic effects and could have potential use (Figure 4).

Step 5 involves switching to a high dose of corticosteroid and the addition of drugs with effects such as inhibiting IgE, IL-4, or IL-5, guided by the phenotypic assessment by an asthma specialist. Herbs that may be useful for these purposes include *Asarum sieboldii*, *Pinellia ternata*, and *Prunus armeniaca* which inhibit IL-4, Schisandra Fructus which inhibits IL-17, *Lepidium apetalum* and *Perilla frutescens* which regulate Th2 helper cell activity, or Anemarrhena Rhizoma, *Eriobotryae Folium*, *Platycodon grandifloras*, *Paeonia lactiflora*, *Bupleurum chinense*, and *Cinnamomi Ramulus* which have a range of effects against multiple targets (Table 2).

3.5. Frequently Prescribed TCM Formulas in Asthma. A total of 16 formulas were identified as frequently prescribed for asthma (Table 3), of which 12 were "stand-alone formulas" which are usually prescribed independently and 4 were "add-on formulas" which are used in addition to “stand-

---

**Table 2: Continued.**

<table>
<thead>
<tr>
<th>Chinese name</th>
<th>Latin name</th>
<th>MOA targeting asthmatic subgroups</th>
<th>Targeted asthmatic phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chai Hu</td>
<td><em>Bupleurum chinense</em></td>
<td>(1) Inhibits IL-4 and IgE (2) Inhibits IL-5 (3) Inhibits IL-17A</td>
<td>(1) Allergen exacerbated asthma (2) Idiopathic eosinophilic asthma (3) Neutrophilic asthma</td>
</tr>
<tr>
<td>Gui Zi Alteration of genetic expression/signaling pathway</td>
<td><em>Cinnamomi Ramulus</em></td>
<td>(1) Inhibits IgE and IL-4</td>
<td>Allergen exacerbated asthma</td>
</tr>
<tr>
<td>Bei Mu</td>
<td><em>Fritillaria cirrhosa D.Don</em></td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

---

**Figure 3:** Chinese medicine targeted therapy on immunopathological pathways of asthma.
alone formulas” during an acute exacerbation [96]. The MOA of the herbs identified in the formulas was analysed, which demonstrated that “stand-alone formulas” contain herbs with beta-agonist, steroid-like effects or leukotriene antagonist mechanisms, or a combination of beta-agonist and steroid-like effects/leukotriene antagonist. However, “add-on formulas” only had either steroid-like effects or regulated T helper cells.

4. Discussion

4.1. Mechanism of Action of Herbs and Concomitant Use of Drugs and Herbs. Despite theoretical differences between TCM and Western medicine, research is increasingly suggesting that herbal medicines have similar MOA to that of Western medicines (Table 1). The understanding of MOA allows characterisation of herbs in relation to Western medicines and improves prescription methods of TCM physicians. For example, TCM physicians will be able to select herbs with beta-agonist effects in patients presenting with acute asthma. It also allows minimisation of possible interactions between herbs and drugs if taken concurrently, and the use of readily available antidotes should occur. Recent research showed that up to 33.6% of patients in the United Kingdom consume both herbal and prescription medicine together [97]. This could result in overdose or interactions when herbs and drugs with similar MOA be consumed concurrently [98, 99]. Herbs such as Gypsum fibrosum and Zingiberis rhizoma which have no known MOA should not be used concurrently with Western medicines to prevent the occurrence of any unknown side effects.

4.2. Standardization of TCM Management of Asthma. TCM physicians traditionally adopt a “Syndrome-Based” approach in diagnosing patients which is determined by the symptoms of the patient, looks of the tongue, and character of the pulse [100]. “Syndrome-Based” approach means that patients with the same diagnosis given by Western doctors might be diagnosed as different syndromes by TCM physicians, and as such, different management would be given. It is also a relatively subjective approach depending on the consulting physician(s) [101]. It would likely result in differences in outcomes for patients. Through the understanding of the underlying MOA of each herb used for asthma, a proposed guideline (Figure 4) can thus be formulated based on existing GINA guidelines [95]. This would ensure a standardized uniform outcome for patients regardless of “syndromes” characterized by TCM physicians and prevent herbs with repetitive or unknown MOA from being prescribed.

Unlike drugs, herbs are usually consumed orally, and their duration of effect has not been elicited. The proposed guideline takes into account the differences in the mode of administration and durations of the effect of herbs despite the similarity in MOA. Similar to existing GINA guidelines, prescription will be stepwise and incremental according to...
4.3. Phenotype Specific Asthma Therapeutic Targeting of Herbs. In addition to the standard therapeutic MOA for asthma, herbs also seem to regulate the activity of inflammatory cells and cytokines by acting on particular pathways in the immunopathology of asthma (Figure 3). This aids not only in understanding the way herbs work but can also be used to target a particular phenotype of asthma, e.g., down-regulation of IgE in allergen-induced asthma. Biologics such as omalizumab, which targets specific cytokines, have long been employed in the management of asthma. Herbs with similar effects could potentially be employed in a similar fashion as biologics.

The therapeutic interventions for different phenotypes include IL-17 antagonist (neutrophilic asthma), IL-4/13 antagonist and anti-IgE (allergen-induced asthma), corticosteroids and IL-5 antagonist (idiopathic eosinophilic asthma), and leukotriene antagonist (aspirin exacerbated asthma) [102].

Herbs which target certain phenotypes through their effect on cytokines (Table 2) should be added after standardized therapy has been given and phenotypic assessment has been conducted, in line with GINA guidelines. This serves as an individualised management for patients with different asthmatic phenotypes and will lead to improved treatment outcomes.

4.4. Analysis of TCM Formulas Used for Asthma. Herbs are typically prescribed in various combinations as “TCM formulas,” rather than individually. They can be broadly divided into “Stand-alone formulas” which can be used independently for diseases and “Add-on Formulas” which are usually added as adjuvants to “Stand-alone formulas” to enhance their therapeutic effects (Table 3). Interestingly, the analysis of “Stand-alone Formulas” has shown that despite the differences in herbs used, formulas generally consist of herbs with β-agonist and steroid-like effects as recommended by GINA guidelines [95]. On the other hand, “Add-on Formulas” consist of herbs with steroid-like effects or

<table>
<thead>
<tr>
<th>Formula (Chinese)</th>
<th>Formulas</th>
<th>Key ingredients</th>
<th>Main MOA</th>
<th>Individual/add-on formula</th>
</tr>
</thead>
<tbody>
<tr>
<td>治喘方</td>
<td>Dong Shi Zhi Chuan Ji Ben Fang</td>
<td>Ephedra sinica Stapf, Prunus armeniaca, and Pheretima aspergillum</td>
<td>β-Agonist and leukotriene antagonist</td>
<td>Individual</td>
</tr>
<tr>
<td>麻杏石甘汤</td>
<td>Ma Xing Shi Gan Tang</td>
<td>Ephedra sinica Stapf, Glycyrrhiza uralensis, and Prunus armeniaca</td>
<td>β-Agonist and steroid-like effects</td>
<td>Individual</td>
</tr>
<tr>
<td>三拗汤</td>
<td>San Ao Tang</td>
<td>Prunus armeniaca and Glycyrrhiza uralensis</td>
<td>β-Agonist and steroid-like effects</td>
<td>Individual</td>
</tr>
<tr>
<td>芫桂杏甘草汤</td>
<td>Fu Ling Xing Ren Gan Cao Tang</td>
<td>Glycyrrhiza uralensis, Pinellia ternata, and Pericarpium Citri Reticulatae</td>
<td>β-Agonist and steroid-like effects</td>
<td>Individual</td>
</tr>
<tr>
<td>六君子汤</td>
<td>Liu Jun Zi Tang</td>
<td>Ephedra sinica Stapf, Asarum sieboldii, Glicyrrhiza uralensis, Schisandra Fructus, and Pinellia ternata</td>
<td>β-Agonist and steroid-like effects</td>
<td>Individual</td>
</tr>
<tr>
<td>芫桂术甘汤</td>
<td>Ling Gui Shu Gan Tang</td>
<td>Cinnamomi Ramulus and Glycyrrhiza uralensis</td>
<td>β-Agonist and steroid-like effects</td>
<td>Individual</td>
</tr>
<tr>
<td>小柴胡汤</td>
<td>Xiao Chai Hu Tang</td>
<td>Bupleurum chinense, Scutellaria baicalensis, Pinellia ternata, and Glycyrrhiza uralensis</td>
<td>β-Agonist and steroid-like effects</td>
<td>Individual</td>
</tr>
<tr>
<td>小青龙汤</td>
<td>Xiao Qing Long Tang</td>
<td>Ephedra sinica Stapf, Paeonia lactiflora, Asarum sieboldii, Glycyrrhiza uralensis, Cinnamomi Ramulus, Schisandra Fructus, and Pinellia ternata</td>
<td>β-Agonist and steroid-like effects</td>
<td>Individual</td>
</tr>
<tr>
<td>芫芍甘草汤</td>
<td>Shao Yao Gan Cao Tang</td>
<td>Paeonia lactiflora and Glycyrrhiza uralensis</td>
<td>β-Agonist and steroid-like effects</td>
<td>Individual</td>
</tr>
</tbody>
</table>
assist in the regulation of T helper cells. However, none of the formulas have proceeded beyond step 3 of the GINA guidelines which could involve the addition of anticholinergics or leukotriene antagonists.

In addition, some formulas consist of several herbs with the same MOA, e.g., Ma Xing Shi Gan Tang which comprises of Ephedra sinica Stapf and Glycyrrhiza uralensis, both of which exerts the β-agonistic effect and Gui Zhi Jia Hou Po Xing Ren Tang which is made up of Magnolia officinalis and Glycyrrhiza uralensis, both of which exert steroid-like effects. Unknowingly, Ma Xing Shi Gan Tang could result in arrhythmias as a result of excessive β-adrenergic activity, while Gui Zhi Jia Hou Po Xing Ren Tang could result in iatrogenic-induced Cushing syndrome, one of the well documented side effects of steroids especially in systemic steroids administration [103]. Gui Zhi Jia Hou Po Xing Ren Tang should therefore be avoided and let alone as an “Add-on Formula,” as the “Stand-alone Formula,” it is added onto and might already consist of steroidal elements. In addition, one of the existing formulas (Dong Shi Zhi Chuan Ji Ben Fang) also proceeded to include herbs with leukotriene antagonist activity without first including herbs with steroid-like effects as per GINA guidelines. This will likely result in the suboptimal management of patients with asthma.

5. Conclusion
With a rising number of patients seeking TCM [104], it is paramount for TCM physicians to understand the underlying MOA of herbs. This will allow the standardization of prescribing and result in a more guideline-based approach. In line with this approach, herbs with repetitive or unknown MOA should be avoided to reduce the risk of side effects. Both TCM physicians and doctors should also be wary of possible herb-drug interactions. A guideline-based approach will also allow greater continuity of care should a patient wish to transfer between TCM and Western medicine and prevent under or overmedication. However, patients should still seek the advice of their doctors prior to stopping medications.

Further research on Gypsum fibrosum and Zingiberis rhizoma to identify their underlying MOA is recommended.

Data Availability
The data used to support the findings of this study are available online.

Disclosure
Wong L. H. and Tay L. are the co-first authors.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

References
Evidence-Based Complementary and Alternative Medicine


Evidence-Based Complementary and Alternative Medicine


Evidence-Based Complementary and Alternative Medicine


[90] Z. Q. Wu, *Study on the Anti-allergic Effect and Mechanism of Different Extraction from Ramulus Cinnamomi,* Chengdu University of T.C.M., Chengdu, China, 2015.


